Personalis (NASDAQ:PSNL) Upgraded at Wall Street Zen

Personalis (NASDAQ:PSNL) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also recently commented on the company. Morgan Stanley dropped their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Needham & Company LLC raised their target price on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Finally, BTIG Research dropped their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

Shares of PSNL opened at $11.40 on Friday. The business’s 50-day moving average is $6.86 and its two-hundred day moving average is $8.10. The company has a market capitalization of $1.19 billion, a P/E ratio of -11.18 and a beta of 1.96. Personalis has a fifty-two week low of $3.84 and a fifty-two week high of $11.85.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Analysts forecast that Personalis will post -1.06 EPS for the current year.

Insider Transactions at Personalis

In related news, CFO Aaron Tachibana sold 38,799 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.58, for a total value of $449,292.42. Following the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at approximately $2,302,486.14. This trade represents a 16.33% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 80,091 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $11.02, for a total transaction of $882,602.82. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at $2,600,565.72. This represents a 25.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 138,799 shares of company stock worth $1,551,292 over the last ninety days. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Aberdeen Group plc lifted its stake in Personalis by 36.1% in the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock valued at $25,869,000 after buying an additional 861,948 shares in the last quarter. Oracle Investment Management Inc. purchased a new position in Personalis in the 3rd quarter valued at about $1,496,000. ARK Investment Management LLC lifted its stake in Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after buying an additional 802,268 shares in the last quarter. D.A. Davidson & CO. purchased a new position in Personalis in the 4th quarter valued at about $1,158,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in Personalis in the 4th quarter valued at about $2,308,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.